国药控股(01099)发布年度业绩，归母净利润71.55亿元同比增加1.5% 末期股息每股0.69元

智通财经03-23

智通财经APP讯，国药控股(01099)发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元(单位下同)，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。营运效率提升方面，本集团锚定规模效应和成本领先战略，推进费用压降和精益化管理。截至2025年末，本集团整体费用率同比下降0.25个百分点，有力...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621554742?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-23 07:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621554742","market":"sh","top_or_hot":-1,"title":"国药控股(01099)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元","media":"智通财经","content":"<div>\n<p>智通财经APP讯，国药控股(01099)发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元(单位下同)，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。营运效率提升方面，本集团锚定规模效应和成本领先战略，推进费用压降和精益化管理。截至2025年末，本集团整体费用率同比下降0.25个百分点，有力...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417113.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国药控股(01099)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国药控股(01099)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 07:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1417113.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，国药控股(01099)发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元(单位下同)，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。营运效率提升方面，本集团锚定规模效应和成本领先战略，推进费用压降和精益化管理。截至2025年末，本集团整体费用率同比下降0.25个百分点，有力...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417113.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIG","symbol_name":"股利增长指数ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417113.html","article_id":"2621554742","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621554742","pubTimestamp":1774221459,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，国药控股 发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。报告期内，经营性现金流实现净流入为141.38亿元，较上年同期多流入25.92亿元，现金流管理成效突出;应收账款增幅显著收窄，应收账款专项治理显效;资产负债率同比下降2.12个百分点。报告期内，三大主营业务板块延续差异化发展态势。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"VIG":"股利增长指数ETF-Vanguard","01099":"国药控股"},"translate_title":"Sinopharm Holdings (01099) released its annual results, and the net profit attributable to the parent was 7.155 billion yuan, an increase of 1.5% year-on-year. The final Dividend was 0.69 yuan per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1.5,"VIG":1.5},"content_text":"智通财经APP讯，国药控股(01099)发布截至2025年12月31日止年度业绩，该集团取得收入人民币5751.68亿元(单位下同)，同比减少1.6%;母公司持有者应占溢利71.55亿元，同比增加1.5%;每股盈利2.29元，拟派发末期股息每股0.69元。营运效率提升方面，本集团锚定规模效应和成本领先战略，推进费用压降和精益化管理。截至2025年末，本集团整体费用率同比下降0.25个百分点，有力抵消毛利额的下降影响。报告期内，经营性现金流实现净流入为141.38亿元，较上年同期多流入25.92亿元，现金流管理成效突出;应收账款增幅显著收窄，应收账款专项治理显效;资产负债率同比下降2.12个百分点。依托内部治理效能的提升，本集团有效抵御市场波动压力，实现经营溢利率同比增长0.02个百分点，整体业务展现出强劲的抗风险能力与发展韧性，为“十四五”圆满收官及“十五五”战略谋篇布局奠定了坚实基础。2025年，本集团聚焦高质量发展的首要任务，科学研判各区域市场态势和竞争格局，积极拓展市场份额，以改革创新驱动提质增效。报告期内，三大主营业务板块延续差异化发展态势。其中，医药分销板块收入占比达到72.79% ，同比下降0.37个百分点;器械分销板块收入占比达到19.32% ，同比微降0.09个百分点;医药零售板块收入占比达到 6.42% ，同比上升0.50个百分点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621554742","isCrawlerRequest":true}

国药控股(01099)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元

精彩评论

国药控股(01099)发布年度业绩，归母净利润71.55亿元同比增加1.5% 末期股息每股0.69元